

MOLPHARM/2005/012005

**Characterization of Novel Aryl-Ether, Biaryl and Fluorene Aspartic  
Acid and Diaminopropionic Acid Analogs as Potent Inhibitors of the  
High-Affinity Glutamate Transporter EAAT2**

John Dunlop, H. Beal McIlvain, Tikva Carrick, Brian Jow, Qiang Lu, Dianne Kowal,  
Steven Lin, Alexander Greenfield, Cristina Grosanu, Kristi Fan, Robert Petroski, John  
Williams, Alan Foster & John Butera

Discovery Neuroscience (JD, BM, TAC, BJ, QL, DK, SL) and Chemical & Screening  
Sciences (AG, CG, KF, JB), Wyeth Research, CN 8000, Princeton, NJ 08543, USA;  
Neurocrine Biosciences (RP, JW, AF), 12790 El Camino Real, San Diego, CA 92130

MOLPHARM/2005/012005

a) *Running Title:* Novel Potent Blockers of EAAT2

b) *Address for all correspondence:*

John Dunlop PhD, Neuroscience Discovery Research, Wyeth Research, CN 8000

Princeton, NJ 08543, Tel 732-274-4193, Fax 732-274-4292, Email dunlopj@wyeth.com

c) Number of text pages: 32

Number of tables: 1

Number of figures: 10

Number of references: 25

Number of words in abstract: 233

Number of words in introduction: 656

Number of words in discussion: 1043

d) Non standard abbreviations:

EAAT2, excitatory amino acid transporter; FLIPR, fluorometric imaging plate reader; L-AP4, L-(+)-2-amino-4-phosphonobutyric acid; LY341495, (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid; LY354740, (+)-2-aminobicyclo[3.1.0.]hexane-2,6,-dicarboxylic acid; WAY-213613, N<sup>4</sup>-[4-(2-bromo-4,5-difluorophenoxy)phenyl]-L-asparagine; WAY-213394, N<sup>4</sup>-(2'-methyl-1,1'-biphenyl-4-yl)-L-asparagine; WAY-212922, N<sup>4</sup>-[7-(trifluoromethyl)-9H-fluoren-2-yl]-L-asparagine; WAY-211686, 3-{[(4'-chloro-2-methyl-1,1'-biphenyl-4-yl)carbonyl]amino}-L-alanine

e) Recommended section: Neuropharmacology

MOLPHARM/2005/012005

## Abstract

In this study, we describe the pharmacological characterization of novel aryl-ether, biaryl and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of EAAT2, the predominant glutamate transporter in forebrain regions. The rank order of potency determined for inhibition of human EAAT2 was WAY-213613 (N<sup>4</sup>-[4-(2-bromo-4,5-difluorophenoxy)phenyl]-L-asparagine) (IC<sub>50</sub>, 85 ± 5 nM) > WAY-213394 (N<sup>4</sup>-(2'-methyl-1,1'-biphenyl-4-yl)-L-asparagine) (145 ± 22 nM) = WAY-212922 (N<sup>4</sup>-[7-(trifluoromethyl)-9H-fluoren-2-yl]-L-asparagine) (157 ± 11 nM) = WAY-211686 (3-[[4'-chloro-2-methyl-1,1'-biphenyl-4-yl]carbonyl]amino}-L-alanine) (190 ± 10 nM). WAY-213613 was the most selective of the compounds examined with IC<sub>50</sub>s for inhibition of EAAT1 and EAAT3 of 5 and 3.8 μM, respectively, corresponding to a 59- and 45-fold selectivity toward EAAT2. An identical rank order of potency (WAY-213613 (35 ± 7 nM) > WAY-213394 (92 ± 13 nM) = WAY-212922 (95 ± 8 nM) = WAY-211686 (101 ± 20 nM)) was observed for the inhibition of glutamate uptake in rat cortical synaptosomes, consistent with the predominant contribution of EAAT2 to this activity. Kinetic studies with each of the compounds in synaptosomes revealed a competitive mechanism of inhibition. All compounds were determined to be non-substrates by evaluating both the stimulation of currents in EAAT2-injected oocytes and the heteroexchange of D-[<sup>3</sup>H]aspartate from cortical synaptosomes. WAY-213613 represents the most potent and selective inhibitor of EAAT2 identified to date. Taken in combination with its selectivity over ionotropic and metabotropic glutamate receptors this compound represents a potential tool for the further elucidation of EAAT2 function.

MOLPHARM/2005/012005

## Introduction

Glutamate is the predominant excitatory neurotransmitter in the mammalian central nervous system. Glutamate transmission is mediated via interaction with the ligand-gated ion channel receptors, termed the ionotropic receptors, and the seven transmembrane domain G-protein coupled receptors, termed metabotropic glutamate receptors (Barnard, 1997; Schoepp et al., 1999). Activation of these receptors is responsible for the physiological actions of glutamate, while paradoxically over-stimulation of the ionotropic receptors contributes to the excitotoxic actions attributed to glutamate. Consequently, synaptic glutamate levels must be tightly regulated in order to maintain the integrity of synaptic transmission and to limit or prevent the pathophysiological activity of this excitatory neurotransmitter.

A family of high-affinity Na<sup>+</sup>-dependent glutamate transporters expressed in the plasma membranes of both neurones and astroglia is responsible for the clearance of extracellular glutamate by mediating the cellular uptake of glutamate in a process driven largely by the energy of the transmembrane Na<sup>+</sup> gradient (see review by Danbolt, 1999). Five members of this transporter family have been identified by molecular cloning and are designated EAAT1/GLAST, EAAT2/GLT-1, EAAT3/EAAC1, EAAT4 and EAAT5 (Kanai and Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Arriza et al., 1994, 1997; Fairman et al., 1995). Among the transporter subtypes EAAT2 accounts for the bulk of transport activity measured in forebrain preparations. The pharmacological profile of glutamate transport measured in rat forebrain preparations is well correlated with the pharmacology of the cloned rat GLT-1 and human EAAT2 subtypes expressed in mammalian cell lines (Dunlop et al., 1999; Tan et al., 1999). Moreover, transgenic mice with a targeted

MOLPHARM/2005/012005

deletion of the EAAT2 transporter lose greater than 90% of the forebrain glutamate transport capacity and exhibit increased vulnerability to an experimental head trauma insult (Tanaka et al., 1997). Experiments using antisense oligonucleotides to knock down levels of EAAT2 resulted in reduced glutamate transport capacity, elevated extracellular glutamate and increased neurodegeneration (Rothstein et al., 1996) providing another line of evidence in support of a major role of EAAT2 in glutamate clearance.

A pharmacological elucidation of the functional role of EAAT2 has been hampered by the lack of potent and selective transport inhibitors. Widely utilized pharmacological tools such as the pyrrolidine dicarboxylates (Bridges et al., 1991), aminocyclobutane dicarboxylates (Fletcher et al., 1991) and carboxycyclopropyl glycines (Nakamura et al., 1993) suffer from combinations of poor selectivity across EAAT subtypes, rather modest potencies in the micromolar range and cross reactivity with glutamate receptor targets. More recently, the *threo*- $\beta$ -hydroxyaspartate derivative TBOA (*threo*- $\beta$ -benzyloxyaspartate) and the novel heptane dicarboxylate WAY-855 (3-amino-tricyclo[2.2.1.0<sup>2,6</sup>]heptane-1,3-dicarboxylic acid) have been reported as novel EAAT inhibitors (Lebrun et al., 1997; Shimamoto et al., 1998; Dunlop et al., 2003), and these agents provide some improvement over the earlier compounds. Subsequent structure activity relationship studies with TBOA have lead to the identification of nanomolar potent EAAT2 inhibitors with the most selective agent CNB-TBOA ((2S,3S)-3-[3-(4-methoxybenzoylamino)benzyloxy]aspartate)) exhibiting 39-fold selectivity over EAAT3 (Shimamoto et al., 1998). Such agents are likely to be better tools for the characterization of transporter function.

MOLPHARM/2005/012005

In this study we present the in vitro pharmacological characterization of novel chemotypes possessing potent and EAAT2 preferring inhibitory activity. Compounds were designed by appending a lipophilic load on a relatively polar aspartic acid or aspartic acid-like (diaminopropionic acid) headpiece. Based on our hypothetical binding site interaction model, generated based on a set of literature and in-house EAAT inhibitors, additional aromatic centers observed in these novel compounds are implicated in the enhancement of EAAT2 potency and concomitant improvement in selectivity over EAAT1 and EAAT3. The synthesis and structure-activity relationship of these series of compounds will be presented elsewhere. These novel compounds offer advantages over existing EAAT2 inhibitors in terms of potency, selectivity and ease of synthesis. WAY-213613 (N<sup>4</sup>-[4-(2-bromo-4,5-difluorophenoxy)phenyl]-L-asparagine) was found to be the most potent and selective of the compounds described herein inhibiting EAAT2 with an IC<sub>50</sub> of 85 nM, and exhibiting 59- and 45-fold selectivity over EAAT1 and EAAT3, respectively. Moreover, WAY-213613 was devoid of ionotropic and metabotropic glutamate receptor activity indicating it to be a highly EAAT2 preferring transporter ligand.

MOLPHARM/2005/012005

## Materials and Methods

**Uptake in Stable Cell Lines.** Stable HEK cell lines expressing each of the human glutamate transporter subtypes EAAT1-3 were maintained in T175 flasks at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. Cells were detached and replated at 50,000 cells/well in 96 well culture plates the day prior to measurements of glutamate uptake. Uptake assays were performed in Dulbecco's phosphate buffered saline (D-PBS) in the presence of 1 μM glutamate and 0.2 μCi/ml L-[<sup>3</sup>H]glutamate (specific activity 20-30 Ci/mmol; 1 mCi/ml) in a final volume of 100 μl. Cells were washed with D-PBS before incubation with substrate in the absence or presence of compounds for 20 min at room temperature. Assays were stopped by aspiration followed by two ice-cold D-PBS washes. Cells were solubilized with 0.5 N NaOH before addition of Microscint 20 for the determination of [<sup>3</sup>H] accumulation in the wells using a Packard TopCount. Uptake was linear for incubation times up to 30 min (data not shown), thus data were analyzed as true rates. Non-specific uptake was corrected for by performing all experiments in the absence and presence of sodium (replacement of sodium chloride with choline chloride). Sodium independent uptake accounted for ≤ 10% of total uptake and was subtracted prior to any further data calculation.

**Uptake in Rat Cortical Synaptosomes.** P2 synaptosomal fractions isolated from rat cerebral cortex were prepared by homogenization of tissue in ice cold isolation medium (310 mM sucrose, 10 mM HEPES, pH 7.4) followed by centrifugation at 1000 g for 5 min. The resulting supernatant was collected and centrifuged at 20,000 g for 20 min to obtain the crude synaptosomal P2 pellet which was used for uptake studies at a protein

MOLPHARM/2005/012005

concentration of 1 mg/ml in HEPES-buffered saline (HBS). L-[<sup>3</sup>H]glutamate (specific activity 20-30 Ci/mmol; 1 mCi/ml) uptake was assayed in a final volume of 300 µl HBS containing 50 µg synaptosomal protein, 1 µM L-glutamate and 0.25 µCi/assay L-[<sup>3</sup>H]glutamate in the absence and presence of drug for the determination of IC<sub>50</sub> values. Kinetic experiments were performed in the presence of 0.25 µCi/assay L-[<sup>3</sup>H]glutamate over a range of cold L-glutamate concentrations in both the absence and presence of compounds. Uptake assays were incubated for 5 min at room temperature and were terminated by filtration on a Packard 96 well Unifilter (Whatman GF/B) plate followed by two washes with ice-cold buffer. Microscint 20 was added directly to filter plates for the determination of [<sup>3</sup>H] retained on the filters using a Packard TopCount. Uptake was linear over the 5 min incubation period and data were corrected to represent sodium dependent uptake.

**Oocyte Studies.** EAAT mRNAs were injected into defolliculated stage IV or V *Xenopus* oocytes (10ng/oocyte), and the membrane currents were recorded 3-7 days later. Recording solution ND96 contained 96 mM NaCl, 2 mM KCl, 1 mM CaCl<sub>2</sub>, 1mM MgCl<sub>2</sub>, 5 mM HEPES, pH 7.4. Two electrode voltage clamp recordings were performed at room temperature with a NPI TURBO TEC-03X amplifier, EPC-9 and PULSE program for A/D interface and data acquisition. Microelectrodes were filled with 3 M KCl solution and had resistance around 1 mega Ohm. Cells were clamped at -40 mV, and depolarized to -80 mV for 100 msec where the current was measured at the end of the step protocol. EAAT current amplitude was determined by measuring the difference of the step currents before and after the substrate (10 µM glutamate) applied to the bath.



MOLPHARM/2005/012005

The current was low-pass filtered at 200 Hz, and digitized at 5 kHz. Compounds were dissolved in DMSO as stock, and diluted to final concentration with less than 1% DMSO in the bath. Data were averaged from all oocytes tested and are expressed as mean  $\pm$  S.E.

**Iontropic Glutamate Receptor Assays.** Evaluation of the compounds for effects on ionotropic glutamate receptors was performed by measuring their effects on NMDA and AMPA-induced depolarization of primary cultures of rat hippocampal neurons using a membrane potential sensitive fluorescent dye (FLIPR Membrane Potential Dye, FMP dye, Molecular Devices, Sunnyvale, CA). Minced hippocampi dissected from E18 embryos were incubated at 37°C in 0.01% papain (Worthington, Freehold, NJ), 0.1% dispase (Roche Products, Hertfordshire, UK) and 0.01% DNase (Sigma) dissolved in Hank's Balanced Salt Solution (HBSS). Individual neurons were plated in 96-well format at a density of 100,000 cells/well. Neurons were cultured at 37°C, 5% CO<sub>2</sub> in Neurobasal Media (GIBCO Media #21103-049) supplemented with 2 mM glutamine and 1x B27 supplement (GIBCO # 17504-044). Assays were performed 2 weeks after plating. After removing the culture media, 200  $\mu$ l FMP dye was added to each well and plates were incubated at room temperature for 0.5-1 hr. Agonist activity was evaluated by direct application of the compounds to the plate, following dye loading, after monitoring 15 s baseline fluorescence on-line. For antagonist assays compounds were included during the dye loading step with subsequent stimulation by addition of 50  $\mu$ l depolarizing solution containing 100  $\mu$ M NMDA or AMPA added to each well during FLEX station runs after 15 s reading of base line. As positive controls, 100  $\mu$ M NMDA or AMPA was added to

MOLPHARM/2005/012005

confirm the agonist activity and 30  $\mu$ M Ro-25,6981 or NBQX used to block NMDA- and AMPA-mediated responses, respectively.

**Metabotropic Glutamate Receptor Selectivity Studies.** Stable CHO cell lines expressing either the human mGlu receptors 1, 2 or 4 subtypes were used for functional studies employing the measurement of agonist-stimulated mobilization of intracellular calcium with the fluorometric imaging plate reader (FLIPR). For the G $\alpha$ i-coupled mGlu receptors 2 and 4 functional calcium coupling was facilitated by stable co-expression of a G-protein chimera comprising G $\alpha$ q with the C-terminal five amino acids replaced with those from G $\alpha$ i (Kowal et al., 2003). Cells were maintained and passaged upon reaching approximately 80% confluence. Cells were plated 24 hours prior to the experiment in poly-D-lysine coated 96 well plates at a density of approximately 50,000 cells per well. In preparation of the assay, the confluent monolayer of cells was washed twice with HBSS supplemented with 20 mM HEPES and 2.5 mM probenecid (FLIPR buffer), then the cells were loaded by adding 4  $\mu$ M Fluo-4 AM (Molecular Probes, Eugene, OR) in FLIPR buffer for 1 hour at 37°C. Following loading, the cells were then rinsed twice with FLIPR buffer and intracellular calcium increases following agonist application were detected by measuring increases in fluorescence with the FLIPR. For evaluation of antagonist activity LY341495 ((2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid) was included during the dye-loading step and subsequently stimulated by the addition of an approximate EC<sub>80</sub> concentration of the agonists L-quisqualate, LY354740 ((+)-2-aminobicyclo[3.1.0]hexane-2,6,-dicarboxylic acid) and L-AP4 (L-(+)-2-amino-4-phosphonobutyric acid) for mGlu receptors 1, 2 and 4.

MOLPHARM/2005/012005

**Synaptosomal Exchange.** Rat cortical P2 synaptosome fractions were resuspended in HBS at a protein concentration of 1 mg/ml and incubated in the presence of 1  $\mu$ Ci/ml D- $^3$ H]aspartate (10-15 Ci/mmol; 1 mCi/ml) for 1 hr at room temperature with constant shaking. 100  $\mu$ l synaptosome suspension equilibrated with  $^3$ H] label was diluted into 100  $\mu$ l HBS containing compound at 100  $\mu$ M final concentration immediately after the 1 hr loading period. Under this dilution paradigm the equilibrium established between internal and external  $^3$ H] label is disrupted such that efflux of the label is now favored as the system tends toward re-establishing equilibrium. Consequently, substrate inhibitors, themselves translocated by the transport system, will favor  $^3$ H] efflux via heteroexchange, while non-transportable inhibitors will either have no effect if efflux is limited or will block efflux. Synaptosomes were incubated with drug for 5 min at room temperature followed by centrifugation to separate pellet and supernatant. An aliquot of supernatant was subsequently removed for the determination of  $^3$ H] efflux, a direct index of drug mediated exchange.

**Molecular Modeling.** A dataset was assembled using literature reported EAAT inhibitors and the novel compounds disclosed in the present study (Figure 1). It was assumed that the compounds interact with the transporter(s) in a similar manner, a reasonable assumption given that the compounds have similar mechanism of action as non-transportable, competitive inhibitors of high-affinity glutamate uptake. A 'common feature hypothesis' in Catalyst 4.6 (Acclerys, San Diego) was used to develop the pharmacophore model. The Catalyst pharmacophore model contains the location

MOLPHARM/2005/012005

constraints (3-dimensional coordinates and their tolerance) of commonly used chemical features such as hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), negative ionizable (NI) groups such as carboxylic acid and positive ionizable (PI) groups such as amino groups and ring aromatics. Prior to importing structures into Catalyst, each molecule was fully minimized using MMFF94 force field (Halgren, 1996) and the conformational expansion was performed using the optimal algorithm implemented in Catalyst for each molecule with a maximum of 250 conformers per molecule and an energy range of 15 kcal/mol.

**Data Analysis.** IC<sub>50</sub> values for the dose response curves were generated using a 4 parameter logistic curve fitting model using OriginLabs Origin 7.5 (OriginLabs, Northampton, MA) using the following equation  $y = \frac{A1 - A2}{1 + (x/x0)^p} + A2$  where A1 is the maximum, A2 is the minimum, x0 is the IC<sub>50</sub> and p is the Hill slope coefficient.

MOLPHARM/2005/012005

## Results

**Inhibition of Human EAAT Subtypes.** Figure 1 illustrates the structures of WAY-213613, WAY-213394, WAY-212922 and WAY-211686. Potent EAAT2 inhibitory activity was observed for all four compounds as determined by the inhibition of L-[<sup>3</sup>H]glutamate uptake in a stable HEK cell line expressing the human EAAT2 subtype (Figure 2, Table 1). WAY-213613 was the most potent of the compounds with an IC<sub>50</sub> of 85 ± 5 nM. Primary selectivity determinations for the compounds using HEK cells stably expressing either the human EAAT1 or EAAT3 subtype are also illustrated in Figure 2 with estimated IC<sub>50</sub> values presented in Table 1. In addition to being the most potent compound, WAY-213613 was the most selective of the four exhibiting 59- and 45-fold selectivity over EAAT1 and EAAT3, respectively. The uptake of L-glutamate measured in the EAAT-expressing HEK cell lines in the absence of drug was 10.7, 158.6 and 8.0 pmol/min/mg for EAAT1, 2 and 3, respectively.

**Synaptosomal Uptake Studies.** Additional pharmacological characterization in the form of inhibition of L-[<sup>3</sup>H]glutamate uptake into rat brain cortical synaptosome fractions, a preparation in which EAAT2 contributes the bulk of the measured substrate accumulation, was performed for the compounds in addition to the non-selective and widely utilized pharmacological agent L-*trans*-pyrrolidine-2,4-dicarboxylate (*trans*-2,4-PDC). Concentration-response curves are illustrated in Figure 3. Glutamate uptake in the synaptosomal preparation in the absence of added compound (control) was 2-2.5 nmol/min/mg. Estimated IC<sub>50</sub> values for inhibition of synaptosomal L-[<sup>3</sup>H]glutamate uptake (Table 1) and rank order of potency were essentially identical to those determined for inhibition of EAAT2 with WAY-213613 being the most potent (IC<sub>50</sub>, 35 ± 7 nM) of

MOLPHARM/2005/012005

the compounds evaluated, while the potency of *trans*-PDC was identical to that reported by others ( $IC_{50}$ ,  $1.6 \pm 0.2 \mu M$ ). Kinetic studies were also performed with the synaptosomal preparation to establish mode of inhibition. A double-reciprocal plot (Lineweaver-Burke transformation) of the effect of multiple concentrations of WAY-213613 on the saturable uptake of L-[ $^3H$ ]glutamate is presented in Figure 4 indicative of a competitive mechanism of inhibition. Calculated  $K_I$  values in the presence of 3, 30 and 300 nM WAY-213613 were 15, 41 and 55 nM, respectively, consistent with the inhibitory potency determined for WAY-213613 in the  $IC_{50}$  determination above. Similar experiments performed with WAY-213394, WAY-212922 and WAY-211686 also indicated a competitive mode of inhibition for these compounds (data not shown).

**Oocyte Studies.** Based on its superior potency and EAAT2 selectivity the effect of WAY-213613 on glutamate-induced currents in oocytes was examined. Application of 30  $\mu M$  WAY-213613 (or indeed the other three compounds described in this study) to EAAT2 injected oocytes failed to induce a transporter-like current indicating the compound to be a non-substrate (data not shown). Inward currents evoked by application of glutamate to EAAT2 injected oocytes were blocked in a concentration-dependent manner by WAY-213613 (Figure 5) with an estimated  $IC_{50}$  value of 130 nM. WAY-213613 produced similar concentration-dependent block of glutamate-induced currents in either EAAT1 or EAAT3 injected oocytes (Figure 5) with  $IC_{50}$  values of 48 and 4  $\mu M$ , respectively, reflecting 370- and 31-fold selectivity toward EAAT2.

**Ionotropic Glutamate Receptor Assays.** Using a membrane potential sensitive fluorescent indicator dye we established that addition of either NMDA, in the absence of  $Mg^{2+}$ , or AMPA, in the presence of 250  $\mu g/ml$  concanavalin A to primary cultures of

MOLPHARM/2005/012005

hippocampal neurons produced an increase in dye fluorescence indicative of depolarization. Under these experimental conditions AMPA stimulation can result in activation of both AMPA (directly) and kainate (by indirect release of glutamate) receptors. The depolarizing responses to NMDA or AMPA could be selectively antagonized by either Ro-25,6981 or NBQX, respectively (Figure 6, insets). In contrast, addition of 50  $\mu$ M WAY-213613, WAY-213394, WAY-212922 or WAY-211686 failed to produce a depolarization in these neurons indicating that the compounds failed to activate either NMDA or non-NMDA receptors (data not shown). In addition, the compounds were evaluated for their ability to antagonize depolarizing responses to either NMDA (Figure 6A) or AMPA (Figure 6B) in cultured hippocampal neurons. In the case of WAY-213613, the compound exhibiting the best EAAT2 selectivity, < 40 % inhibition of depolarizing response to either NMDA or AMPA was observed at the highest concentration tested (50  $\mu$ M), while no antagonist effect was observed at 5  $\mu$ M. Based on these data, it can be concluded that WAY-213613 exhibits good selectivity over ionotropic receptors; approximately 60- and 140-fold when compared to its effect on L-[<sup>3</sup>H]glutamate uptake by the cloned EAAT2 subtype or D-[<sup>3</sup>H]aspartate uptake in rat cortical synaptosome fractions (EAAT2 predominant), respectively. WAY-211686 exhibited the most activity toward blocking NMDA-stimulated responses with 31 and 73% inhibition observed at 5 and 50  $\mu$ M, respectively. In the case of AMPA-stimulated responses, WAY-213394 exhibited 20 and 62% inhibition at 5 and 50  $\mu$ M, respectively.

**Metabotropic Glutamate Receptor Assays.** WAY-213613 was evaluated for agonist and antagonist activity at human mGlu receptors 1, 2 and 4, examples of group I, II and III mGlu receptors, respectively. As illustrated in Figure 7, agonist responses were

MOLPHARM/2005/012005

elicited at each receptor subtype by appropriate ligands; 1  $\mu$ M L-quisqualate for mGlu receptor 1, 0.1  $\mu$ M LY354740 for mGlu receptor 2 and 1  $\mu$ M L-AP4 for mGlu receptor 4. In contrast, 100  $\mu$ M WAY-213613 failed to activate any of the mGlu receptors examined (Figure 7). In addition, agonist-stimulated responses were blocked by the mGlu receptor antagonist LY341495, used at concentrations appropriate to each mGlu receptor studied, while 100  $\mu$ M WAY-213613 failed to exhibit antagonist activity at any of the subtypes.

**Synaptosomal Exchange.** Electrophysiological studies in oocytes indicated that WAY-213613 behaved in a manner consistent with a non-substrate inhibitor, failing to activate an inward transporter-like current when applied to EAAT2 injected oocytes yet blocking the glutamate induced currents. A biochemical index which can be used for the determination of substrate versus non-substrate activity is the capacity for drug-mediated heteroexchange of accumulated D- $^3$ H]aspartate substrate (Dunlop, 2001; Griffiths et al., 1994; Koch et al., 1999). Cortical synaptosomes were equilibrated with D- $^3$ H]aspartate prior to the addition of exogenous unlabeled D-aspartate or WAY-213613 to assess drug-mediated  $^3$ H] efflux. As illustrated, addition of exogenous D-aspartate to D- $^3$ H]aspartate loaded synaptosomes stimulated the efflux of  $^3$ H] label (Fig. 8), however WAY-213613 failed to increase  $^3$ H] efflux over control levels consistent with the property of a non-substrate inhibitor.

**Molecular Modeling.** A pharmacophore model containing a number of key features; hydrogen bond acceptor sites, positive ionizable (protonatable nitrogen), negative ionizable (acidic function) and two hydrophobic centers, was developed using both literature reported EAAT inhibitors and the novel compounds presented in this study (Fig. 9). Figure 9 illustrates the fit of L-TBOA and WAY-213613 to the identified



MOLPHARM/2005/012005

pharmacophore indicating both overlapping and distinct conformity to the model. A major distinction between L-TBOA and WAY-213613 is the conformity of the former to all features with the exception of the hydrophobic center 4.11 whereas WAY-213613 fits all features with the exception of the hydrogen bond acceptor. Interestingly, we find that the newly described inhibitors presented in the current study lack a distal acidic group identified by others (Campiani et al., 2001, 2003) as an important pharmacophoric site corresponding to the hydrogen bond acceptor feature in our model. Moreover, the compounds reported in the current study share in common the distal hydrophobic center 4.11. These two distinctive features are candidates to be considered as important in conferring EAAT2 selectivity of our newly identified agents. It is important to note that in the current model the folded form of the aspartate framework in TBOA is well superimposed with the folded form of glutamate (Figure 9), while others have proposed the extended form for the aspartate framework in their model (Koch et al., 1999; Campiani et al., 2001, 2003). Each of these approaches has utilized different modeling scenarios and although we have predicted the folded form of the aspartate framework the other features of the molecule present a very similar configuration in all modeling studies. Moreover, close inspection of the models predicted by Koch et al. and Campiani et al. suggest that these do not predict exactly the same configuration of the aspartate framework. Our model provides a plausible alternative hypothesis for EAAT binding and should be considered in the rational design of new compounds.

To gain further insight into the molecular basis contributing to the pharmacological specificity toward EAAT2 inhibition, the superimposition of the compounds presented in this study with other known EAAT inhibitors including kainate, dihydrokainate and L-

MOLPHARM/2005/012005

TBOA was used to generate composite molecular volumes of the novel agents. The superimpositions of the known and novel ligands are presented (Figure 10A and 10B, respectively), indicating significant lipophilic volume occupied by the novel compounds. Access to this distal lipophilic pocket is achieved consistently with all four novel compounds represented in this study.

MOLPHARM/2005/012005

## Discussion

High-affinity glutamate transporters, termed EAATs, play a critical role in maintaining the fine balance between the physiological actions of glutamate as an excitatory neurotransmitter while preventing the excessive accumulation of extracellular glutamate responsible for excitotoxic cell death. While this fundamental function of the EAATs has been well established a complete elucidation of the relative contribution of individual subtypes and better understanding of their physiological roles has been hampered by the unavailability of potent and selective pharmacological tools.

In the present study, we provide a pharmacological characterization of novel aryl-ether, biaryl and fluorene aspartic acid and diaminopropionic acid analogs as nanomolar potent inhibitors of the high-affinity glutamate transporter EAAT2. Four compounds are described; WAY-213613 (N<sup>4</sup>-[4-(2-bromo-4,5-difluorophenoxy)phenyl]-L-asparagine), WAY-213394 (N<sup>4</sup>-(2'-methyl-1,1'-biphenyl-4-yl)-L-asparagine), WAY-212922 (N<sup>4</sup>-[7-(trifluoromethyl)-9H-fluoren-2-yl]-L-asparagine) and WAY-211686 (3-[(4'-chloro-2-methyl-1,1'-biphenyl-4-yl)carbonyl]amino}-L-alanine). The aryl ether aspartic acid analog WAY-213613 was both the most potent and EAAT2 selective of the compounds studied exhibiting an IC<sub>50</sub> for inhibition of glutamate uptake by the cloned EAAT2 subtype of 85 nM and a 59- and 45-fold separation in potency for EAAT1 and EAAT3, respectively. By comparison, the biaryl substituted aspartic acid analog WAY-213394 although exhibiting similar EAAT2 potency (145 nM) and retaining selectivity toward EAAT3 (45-fold) exhibited reduced selectivity toward EAAT1 (14-fold). Utilizing a fluorene ring scaffold in the aspartic acid analog WAY-212922 resulted in a compound with potent EAAT2 inhibitory activity accompanied by reduced selectivity over EAAT1

MOLPHARM/2005/012005

and EAAT3 of 22- and 12-fold, respectively. Finally, the biaryl substituted diaminopropionic acid analog WAY-211686 also exhibited potent EAAT2 inhibitory activity but suffered from the poorest selectivity of the compounds examined; 9- and 8-fold for EAAT1 and EAAT3, respectively.

The inhibitory potency of the compounds was also confirmed in a native preparation of rat cortical synaptosomes, a model proposed on pharmacological studies to reflect predominantly EAAT2 activity (Dunlop et al., 1999; Tan et al., 1999). Each of the four compounds exhibited similar inhibitory potencies in the synaptosomal preparation and an identical rank order of potency confirming their property as potent glutamate transport inhibitors and providing further evidence for the identity between EAAT2 mediated uptake and uptake by the transport system expressed in rat cortical synaptosomes. Additional studies in the synaptosomal preparation were undertaken to determine that the compounds behaved in a manner consistent with competitive inhibitors suggesting that they overlap with the glutamate recognition site on the transporter. Given that the compounds retain the carboxylic acid moiety it is perhaps not surprising that they would exhibit significant overlap with the glutamate-binding site.

A third index used to estimate the inhibitory activity of the most potent and selective compound WAY-213613 was to evaluate its effect on glutamate-induced currents in oocytes expressing each of the transporters. It was observed that the inhibitory potencies for blocking glutamate-induced currents in both EAAT2 and EAAT3 injected oocytes were identical to those determined in the cell line uptake studies, while a 10-fold weaker  $IC_{50}$  was observed in EAAT1 injected oocytes compared to EAAT1 expressing HEK cells. It is possible that such a discrepancy arises from the indirect index of glutamate

MOLPHARM/2005/012005

translocation provided by current measurements in oocytes reflecting both ion conductances coupled to glutamate translocation and uncoupled ion flux. Studies in oocytes also allowed for the determination that WAY-213613, and the other compounds, failed to activate a transporter-like current when applied to oocytes indicating they were not substrates for the transporter. Such an observation was confirmed with the independent biochemical index of [<sup>3</sup>H] substrate exchange with WAY-213613 failing to promote exchange of accumulated D-[<sup>3</sup>H]aspartate. Given the bulky nature of the substituent group in WAY-213613 it is likely this impedes substrate translocation despite significant overlap with the glutamate recognition site. Taken together, the above observations indicate WAY-213613 to be a potent, EAAT2-preferring, competitive non-substrate inhibitor of EAAT2.

In order to assess the potential utility of WAY-213613 as a pharmacological tool to study EAAT2 it is of importance to provide an assessment of the compound at other principal sites of glutamate action, specifically the ionotropic and metabotropic glutamate receptors. Our studies demonstrate that WAY-213613 was devoid of either agonist or antagonist activity at the ionotropic NMDA and AMPA receptors expressed natively in cultured hippocampal neurons, or at the human mGlu receptors 1, 2 and 4 heterologously expressed in stable cell lines. These results confirm the specificity of WAY-213613 for the glutamate transport system.

In comparison with other known glutamate transporter inhibitors WAY-213613 would appear to be among the most potent and selective of agents reported in the literature. Although kainate and dihydrokainate are known to be selective for EAAT2 compared with the other EAAT subtypes (Arriza et al., 1994) their utility as pharmacological tools

MOLPHARM/2005/012005

are hampered by affinity for ionotropic and metabotropic glutamate receptors, respectively, in addition to their weak (20-50  $\mu\text{M}$ ) potency. Compounds such as the carboxycyclopropyl glycines (Nakamura et al., 1993), aminocyclobutane dicarboxylates (Fletcher et al., 1991) pyrrolidine dicarboxylates (Bridges et al., 1991) and the *threo*-hydroxyaspartate derivative *threo*- $\beta$ -benzyloxyaspartate (TBOA) (Shimamoto et al., 1998; Shigera et al., 2001) have low micromolar potency and do not discriminate between the different EAAT subtypes. More recently, we described WAY-855 as a novel EAAT2 inhibitor with an  $\text{IC}_{50}$  value of 1  $\mu\text{M}$  although this compound only exhibited approximately 10-fold selectivity over EAAT3 (Dunlop et al., 2003). Recent structure-activity relationship studies with TBOA have resulted in the discovery of PMB-TBOA and CNB-TBOA (Shimamoto et al., 2004) as potent EAAT2 inhibitors ( $\text{IC}_{50}$  values of 12 and 36 nM, respectively). However, while these compounds exhibited 22- and 39-fold selectivity over EAAT3 their inhibitory potencies for EAAT1 were essentially the same as those determined for EAAT2. Although WAY-213613 was slightly less potent than either of these agents the compound was more selective over both EAAT1 and EAAT3. By generating a pharmacophore model of known EAAT inhibitors and the novel agents reported here we have identified a number of features associated with the newly identified compounds distinct from known EAAT inhibitors. These include the absence of a distal acidic group acting as a hydrogen bond acceptor identified in other known EAAT inhibitors and the presence of a hydrophobic center conferring significant lipophilic volume to the novel agents. Although by no means definitive these observations may provide insight into structural features for selective EAAT2 binding

MOLPHARM/2005/012005

and provide a working model for further validation toward rational design of selective EAAT inhibitors.

In conclusion, we have identified a number of structurally novel EAAT inhibitors exemplified by WAY-213613 a potent, EAAT2 preferring and non-substrate inhibitor of EAAT2. These newly discovered EAAT2 inhibitors will be important tools to further study EAAT2 function in addition to continuing to refine the structural requirements for binding to different transporter subtypes.

### **Acknowledgements**

We thank Drs. James Barrett and John Moyer for support.

MOLPHARM/2005/012005

## References

Arriza JL, Eliasof S, Kavanaugh MP and Amara SG. (1997) Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. *Proc. Natl. Acad. Sci, U.S.A.* **94**:4155-4160.

Arriza JL, Fairman WA, Wadiche JL, Murdoch GH, Kavanaugh MP and Amara SG (1994) Functional comparison of three glutamate transporter subtypes cloned from human motor cortex. *J. Neurosci.* **14**:5559-5569.

Barnard EA (1997) Inotropic glutamate receptors: new types and new concepts. *Trends Pharmacol. Sci.*, **18**:141-148.

Bridges RJ, Stanley MS, Anderson MW, Cotman CW and Chamberlin AR (1991) Conformationally defined neurotransmitter analogues. Selective inhibition of glutamate uptake by one pyrrolidine-2,4-dicarboxylate diastereomer. *J. Med. Chem.* **34**:717-723

Campiani G, De Angelis M, Armaroli S, Fattorusso C, Catalanotti B, Ramunno A, Nacci V, Novellino E, Grewer C, Ionescu D, Rauen T, Griffiths R, Sinclair C, Fumagalli E and Mennini T (2001) A rational approach to the design of selective substrates and potent nontransportable inhibitors of the excitatory amino acid transporter EAAC1 (EAAT3); new glutamate and aspartate analogues as potential neuroprotective agents. *J. Med. Chem.* **44**:2507-2510.



MOLPHARM/2005/012005

Campiani G, Fattorusso C, De Angelis M, Catalanotti B, Butini S, Fattorusso R, Fiorini I, Nacci V and Novellino E (2003) Neuronal high-affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases. *Curr. Pharm. Design* **9**:599-625.

Danbolt NC (2001) Glutamate uptake. *Prog. Neurobiol.* **65**:1-105.

Dunlop J, Lou Z, Zhang, Y and McIlvain, B (1999) Inducible expression and pharmacology of the human excitatory amino acid transporter 2 subtype of L-glutamate transporter. *Br. J. Pharmacol.* **128**:1485-1490.

Dunlop J, Eliasof S, Stack G, McIlvain HB, Greenfield A, Kowal D, Petroski R and Carrick T (2003) WAY-855 (3-amino-tricyclo[2.2.1.0<sup>2,6</sup>]heptane-1,3-dicarboxylic acid): a novel, EAAT2-preferring, non-substrate inhibitor of high-affinity glutamate uptake. *Br. J. Pharmacol.* **140**:839-846.

Fairman W, Vandenberg RJ, Arizza JL, Kavanaugh MP and Amara SG. (1995) An excitatory amino acid transporter with properties of a ligand gated chloride channel. *Nature* **375**:599-603

Fletcher EJ, Mewett, KN, Drew CA, Allan RD and Johnston, GA (1991) Inhibition of L-glutamate uptake into rat cortical synaptosomes by the conformationally restricted

MOLPHARM/2005/012005

analogue of glutamic acid, cis-1-aminocyclobutane-1,3-dicarboxylic acid. *Neurosci. Lett.*, **121**:133-135.

Halgren TA (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. *J.Comp. Chem.* **17**:490-519.

Kanai Y and Hediger, MA (1992) Primary structure and functional characterization of a high-affinity glutamate transporter. *Nature* **360**:467-471.

Kowal D, Nawoschik S, Ochalski R and Dunlop J (2003) Functional calcium coupling with the human metabotropic glutamate receptor subtypes 2 and 4 by stable co-expression with a calcium pathway facilitating G-protein chimera in Chinese hamster ovary cells. *Biochem. Pharmacol.* **66**:785-790.

Lebrun B, Sakaitani M, Shimamoto K, Yasuda-Kamatani Y and Nakajima T (1997) New beta-hydroxyaspartate derivatives are competitive blockers for the bovine glutamate/aspartate transporter. *J. Biol. Chem.* **272**:20336-20339.

Nakamura Y, Kataoka K, Ishida M and Shinozaki H (1993) (2S,3S,4R)-2(carboxycyclopropyl) glycine, a potent and competitive inhibitor of both glial and neuronal uptake of glutamate. *Neuropharmacology* **32**:833-837.

MOLPHARM/2005/012005

Pines G, Danbolt NC, Bjoras M, Zhang Y, Bendahan A, Eide L, Koepsell H, Storm-Mathisen J, Seeberg E and Kanner BL. (1992) Cloning and expression of a rat brain L-glutamate transporter. *Nature* **360**:64-467.

Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanaly Y, Hediger MA, Wang Y, Schielke JP and Welty DF (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. *Neuron* **16**:675-686.

Schoepp DD, Jane DE and Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. *Neuropharmacology* **38**:1431-1476.

Shigera Y, Shimamoto K, Yasuda-Kamatani Y, Seal RP, Yumoto N, Nakajima T and Amara SG (2001) Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5) *J. Neurochem* **79**:297-302.

Shimamoto K, Lebrun B, Yasuda-Kamatani Y, Sakaitani M, Shigeri Y, Yumoto N and Nakajima T (1998) DL-threo- $\beta$ -benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. *Mol. Pharmacol.* **53**:195-201.

Shimamoto K, Sakai R, Takaoka K, Yumoto N, Nakajima T, Amara SG and Shigeri Y (2004) Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters. *Mol. Pharmacol.* **65**:1008-1015.

MOLPHARM/2005/012005

Storck T, Schulte S, Hofmann K and Stoffel W (1992) Structure, expression and functional analysis of a Na<sup>+</sup>-dependent glutamate/aspartate transporter from rat brain.

*Proc. Natl. Acad. Sci. U.S.A.* **89**:10955-10959.

Tan J, Zelenia O, Correale D, Rothstein JD and Robinson MD (1999) Expression of the GLT-1 subtype of Na<sup>+</sup>-dependent glutamate transporter: pharmacological characterization and lack of regulation by protein kinase C. *J. Pharm. Exp. Ther.*

**289**:1600-1610.

Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M and Wada K (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. *Science* **276**:1699-1702.

MOLPHARM/2005/012005

### **Footnotes**

Address correspondence and reprint request to: John Dunlop, Neuroscience Discovery

Research, CN 8000, Princeton, NJ 08543. email: [dunlopj@wyeth.com](mailto:dunlopj@wyeth.com)

MOLPHARM/2005/012005

## Legends for figures

**Figure 1.** Chemical structures of WAY-213613 ( $N^4$ -[4-(2-bromo-4,5-difluorophenoxy)phenyl]-L-asparagine), WAY-213394 ( $N^4$ -(2'-methyl-1,1'-biphenyl-4-yl)-L-asparagine), WAY-212922 ( $N^4$ -[7-(trifluoromethyl)-9H-fluoren-2-yl]-L-asparagine) and WAY-211686 (3-[[4'-chloro-2-methyl-1,1'-biphenyl-4-yl)carbonyl]amino}-L-alanine), kainate, dihydrokainate and L-TBOA (L-threo-b-benzyloxyaspartate).

**Figure 2.** Log-concentration response curves for the effects of WAY-213613 (A), WAY-213394 (B), WAY-212922 (C) and WAY-211686 (D) on L-[ $^3H$ ]glutamate uptake in stable HEK cells expressing the human EAAT1 (closed triangles), EAAT2 (closed circles) and EAAT3 (closed squares) transporter subtypes. L-[ $^3H$ ]glutamate uptake was measured in the absence or presence of the indicated drug concentrations. Data are expressed as percent control uptake measured in the absence of added compound and represent the mean  $\pm$  SEM from 3 independent experiments.

**Figure 3.** Log-concentration response curves for the effects of WAY compounds and *trans*-2,4-PDC on L-[ $^3H$ ]glutamate uptake into rat cortical synaptosome fractions. Data are expressed as percent control uptake measured in the absence of added compound and represent the mean  $\pm$  SEM from 3 independent experiments.

MOLPHARM/2005/012005

**Figure 4.** Kinetic characterization of the inhibitory effect of WAY-213613 on synaptosomal L-[<sup>3</sup>H]glutamate uptake. L-glutamate uptake was measured in the presence of increasing concentrations of substrate with or without the addition of WAY-213613. Lineweaver-Burk transformations of the saturable uptake data obtained in the absence (closed squares) and presence of 3 (open circles), 30 (open squares) or 300 (closed circles) nM WAY-213613 obtained in a representative experiment are depicted. The profile is consistent with a competitive mode of inhibition and the  $K_i$  values estimated in the presence of 3, 30 and 300 nM WAY-213613 were 15, 41 and 55 nM, respectively.

**Figure 5.** Log-concentration response curves for the effect of WAY-213613 on L-glutamate-induced currents in oocytes expressing the human EAAT1 (closed triangles), EAAT2 (closed circles) and EAAT3 (closed squares) transporter subtypes. 10  $\mu$ M L-glutamate-induced currents were measured in the absence or presence of the indicated drug concentrations. Data are expressed as percent control current measured in the absence of added compound and represent the mean  $\pm$  SEM from 3 independent experiments.

**Figure 6.** Functional evaluation of WAY-213613, WAY-213394, WAY-212922 and WAY-211686 in cultured hippocampal neurons as measured by FLIPR membrane potential sensitive dye. The ability of compounds (0.5 – 50  $\mu$ M) to antagonize depolarizing responses to either NMDA (A) or AMPA (B) was examined. Increase in fluorescence ( $\Delta F$ ) following NMDA or AMPA application was normalized to 1.0 and data are expressed relative to  $\Delta F$  observed in the absence of added compound. Data are presented from triplicate determinations ( $\pm$  SEM). Insets; antagonism of NMDA-

MOLPHARM/2005/012005

mediated responses by Ro-25,6981 (A, inset) and AMPA-mediated responses by NBQX (B, inset).

**Figure 7.** Functional evaluation of WAY-213613 at representative group I, II and III mGlu receptor subtypes as measured by the calcium indicator dye FLUO-4-AM. WAY-213613 was examined in the absence and presence of EC<sub>80</sub> concentrations of the agonists L-quis, LY354740 and L-AP4 at mGlu receptors 1,2 and 4, respectively. An approximate EC<sub>50</sub> concentration of LY341495 for each subtype was utilized as a positive control for antagonist determinations. Data are expressed as a percentage of the agonist EC<sub>80</sub> response observed at each receptor. Calcium responses are presented in triplicate  $\pm$  SEM.

**Figure 8.** Effect of WAY-213613 on synaptosomal exchange of accumulated D-[<sup>3</sup>H]aspartate. Synaptosomes were pre-equilibrated with D-[<sup>3</sup>H]aspartate for 1 hr prior to dilution into buffer with or without compounds at 2x concentration for 5 min followed by centrifugation to separate pellet and supernatant. An aliquot of supernatant was removed for the determination of [<sup>3</sup>H] efflux and data are expressed as CPM in the supernatant fraction representing mean values  $\pm$  SEM from 3 independent experiments.

**Figure 9.** Pharmacophore model constructed using literature reported and novel WAY EAAT inhibitors. Key features of the model are indicated with the carbon atoms of L-TBOA highlighted in magenta, those from WAY-213613 shown in green and glutamate in yellow. HBA, hydrogen bond acceptor (note white arrow indicates direction of hydrogen bonding); NegIonizable, negative ionizable; PosIonizable, positive ionizable. Numbers assigned to each of the chemical features (e.g., 4.21) arbitrarily in Catalyst.



MOLPHARM/2005/012005

**Figure 10.** Composite molecular volumes generated by overlay of known and newly identified WAY EAAT inhibitors. The non-selective EAAT inhibitors kainate (carbon atoms in yellow), dihydrokainate (magenta) and L-TBOA (white) are superimposed in A compared with the extra volume occupied only by the newly identified compounds shown in B; WAY-213613 (purple), WAY-213394 (green), WAY-212922 (orange) and WAY-211686 (cyan).

MOLPHARM/2005/012005

**Table 1.**

Estimated IC<sub>50</sub> values for the inhibition of L-[<sup>3</sup>H]glutamate uptake by human EAAT subtypes and D-[<sup>3</sup>H]aspartate uptake into rat cortical synaptosome fractions. Data are the mean ± SEM from 3 independent experiments.

	EAAT2	EAAT1	EAAT3	Synaptosomes
			nM	
WAY-213613	85 ± 5	5004 ± 1904	3787 ± 1927	35 ± 7
WAY-213394	145 ± 22	1971 ± 162	6561 ± 2690	92 ± 13
WAY-212922	157 ± 11	3426 ± 815	1837 ± 654	95 ± 8
WAY-211686	190 ± 10	1681 ± 243	1453 ± 282	101 ± 20







Figure 1  
MOLPHARM/2005/012005




**Figure 2**  
MOLPHARM/2005/012005



**Figure 3**  
MOLPHARM/2005/012005



**Figure 4**  
MOLPHARM/2005/012005



**Figure 5**  
MOLPHARM/2005/012005




Figure 6  
MOLPHARM/2005/012005








Figure 7  
MOLPHARM/2005/012005




**Figure 8**  
**MOLPHARM/2005/012005**




**Figure 9**  
**MOLPHARM/2005/012005**

A



B



**Figure 10**  
**MOLPHARM/2005/012005**